

IFW



32692

Customer Number

Patent  
Case No.: 58211US004

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Named Inventor: FINK, JASON R.  
Application No.: 10/807934 Group Art Unit: 1653  
Filed: March 24, 2004 Examiner: Unknown  
Title: SELECTIVE ACTIVATION OF CELLULAR ACTIVITIES MEDIATED THROUGH  
A COMMON TOLL-LIKE RECEPTOR

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

<b>CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR § 1.8(a)]</b>	
I hereby certify that this correspondence is being:	
<input type="checkbox"/>	deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
<input checked="" type="checkbox"/>	transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) 872-9306.
<u>23 DEC. 2004</u>	<u>Laci Burhop</u>
Date	Signed by: Laci Burhop

Dear Sir:


Pursuant to 37 CFR §§ 1.56, 1.97, and 1.98, enclosed is a completed Form PTO-1449, citing references submitted for consideration by the Examiner. It is respectfully requested that the Examiner initial and return the enclosed Form PTO-1449 to indicate that each reference has been considered.

Copies of any cited foreign patents, foreign publications, non-patent literature documents, and any pending U.S. applications filed before June 30, 2003, are enclosed. Copies of any pending U.S. applications filed after June 30, 2003 that can be accessed on the USPTO's IFW system are not enclosed as per USPTO Waiver dated September 21, 2004. Copies of any U.S. patents and published U.S. patent applications are not enclosed.

If a first Office Action on the merits has been mailed prior to the mailing date of this document, please charge the fee for consideration of an Information Disclosure Statement set forth in 37 CFR § 1.17(p), and if necessary, please charge any additional fees, or credit any overpayment to Deposit Account No. 13-3723.

Respectfully submitted,

12/22/2004  
\_\_\_\_\_  
Date

By:   
\_\_\_\_\_  
Christopher D. Gram, Reg. No.: 43,643  
Telephone No.: (651) 733-1507

Office of Intellectual Property Counsel  
3M Innovative Properties Company  
Facsimile No.: 651-736-3833

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Filing Date

March 24, 2004

First Named Inventor

Fink, Jason R.

Art Unit

1653

Examiner Name

Unknown

Attorney Case Number

58211US004

(Use as many sheets as necessary)

Page 1 of 2

## U.S. Patent Documents

Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A1	US- 6,706,728	03-16-2004	Hedenstrom et al.	
	A2	US- 6,743,920	06-01-2004	Lindstrom et al.	
	A3	US- 6,756,382	06-29-2004	Coleman et al.	
	A4	US- 6,818,650	11-16-2004	Griesgraber	
	A5	US- 2003/0130299 A1	07-10-2003	Crooks et al.	
	A6	US- 2003/0161797 A1	08-28-2003	Miller et al.	
	A7	US- 2003/0199538 A1	10-23-2003	Skwierzynski et al.	
	A8	US- 2004/0091491	05-13-2004	Kedl et al.	
	A9	US- 2004/0132079	07-08-2004	Gupta et al.	
	A10	US- 2004/0141950	07-22-2004	Noelle et al.	
	A11	US- 2004/0147543	07-29-2004	Hays et al.	
	A12	US- 2004/0162309	08-19-2004	Gorden et al.	
	A13	US- 2004/0171086	09-02-2004	Fink et al.	
	A14	US- 2004/0175336	09-09-2004	Egging et al.	
	A15	US- 2004/0176367	09-09-2004	Griesgraber et al.	
	A16	US- 2004/0180919	09-16-2004	Miller et al.	
	A17	US- 2004/0181130	09-16-2004	Miller et al.	
	A18	US- 2004/0181211	09-16-2004	Graham et al.	
	A19	US- 2004/0191833	09-30-2004	Fink et al.	
	A20	US- 2004/0192585	09-30-2004	Owens et al.	
	A21	US- 2004/0202720	10-14-2004	Wightman et al.	
	A22	US- 2004/0214851	10-28-2004	Birmachu et al.	

## Foreign Patent Documents

Exam. Init.*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
		Ctry. Code	Number-KindCode (If known)				
	B1	WO	03/097641 A2	11-27-2003			
	B2	WO	04/053057 A2	06-24-2004			
	B3						

\*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Substitute for form 1449/PTO (modified)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)  Page 2 of 2	<b>Application Number</b>	<b>10/807934</b>
	<b>Filing Date</b>	<b>March 24, 2004</b>
	<b>First Named Inventor</b>	<b>Fink, Jason R.</b>
	<b>Art Unit</b>	<b>1653</b>
	<b>Examiner Name</b>	<b>Unknown</b>
	<b>Attorney Case Number</b>	<b>58211US004</b>

Foreign Patent Documents							
Exam. Init.*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
		Ctry. Code	Number-KindCode (If known)				
	B4						
	B5						

OTHER DOCUMENTS			
Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation (Check if yes)
	C1	Vasilakos, J. P. et al., "Adjuvant Activities of Immune Response Modifier R-848: Comparison with CpG ODN". <u>Cellular Immunology</u> . 2000, Vol. 204, pages 64-74.	
	C2	Wagner, T.L. et al., "Modulation of TH1 and TH2 Cytokine Production with the Immune Response Modifiers, R-848 and Imiquimod". <u>Cellular Immunology</u> . 1999, Vol. 191, pages 10-19.	
	C3	Hornung et al., "Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides <sup>1</sup> ", <u>The Journal of Immunology</u> , 2002, 168; pgs. 4531-4537.	
	C4	Hemmi et al., "Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent Signaling pathway", <u>Nature Immunology</u> , vol. 3, no. 2; February 2002; pgs. 196-200.	
	C5	Medzhitov, "Toll-Like Receptors and Innate Immunity", <u>Nature Reviews Immunology</u> , Vol. 1; November 2001, pgs. 135-145.	
	C6	Jurk et al. "Human TLR7 and TLR8 independently confer responsiveness to the antiviral compound R-848", <u>Nature Immunology</u> , June 2002, vol. 3, no. 6; pg. 1.	
	C7	Akira et al., "Toll-like receptors: critical proteins linking innate and acquired immunity", <u>Nature Immunology</u> , August 2001, vol. 2, no. 8; pgs. 675-680.	
	C8	Heil et al.; "Synthetic immunostimulatory compounds activate immune cells via TLR7 and TLR8"; 33th Annual Meeting of the Deutsche Gessellschaft für Immunologie, Marburg 2002 - Abstract C.6	

<b>*Examiner:</b>	<b>Date Considered:</b>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	